Navigation Links
Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
Date:6/25/2010

and complements the NIH funding to Soligenix for the development of RiVax™. The full article (Marconescu et. al., "Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication," Vaccine) is available online at http://dx.doi.org/10.1016/j.vaccine.2010.05.045

About RiVax™

RiVax™ is Soligenix's proprietary vaccine developed to protect against exposure to ricin toxin and is the most advanced vaccine in the company's portfolio. RiVax™ induces a protective immune response in animal models of ricin exposure and is currently being evaluated in humans. One human Phase 1 clinical trial has been completed and a second trial is currently being conducted.

Results of the first Phase 1 clinical trial of RiVax™ indicated that the immunogen was safe and induced antibodies anticipated to protect humans from ricin exposure. The outcome of the study was published in the Proceedings of the National Academy of Sciences (Vitetta et al., 2006, PNAS, 105:2268-2273). The second trial, sponsored by UT Southwestern, is currently evaluating a more potent formulation of RiVax™. Soligenix has developed processes for large-scale manufacturing and is further establishing correlates of the human immune response in non-human primates.

The development of RiVax™ has been sponsored through a series of overlapping challenge grants (UC1) and cooperative grants (U01) from the NIH, granted to Soligenix and to UT Southwestern where the vaccine originated. The second clinical trial is being supported by a grant to UT Southwestern from the
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the reporting of data ... Melphalan Hydrochloride for Injection with the Delcath Hepatic ... poster presentation at the Society of Surgical Oncology ...
(Date:3/26/2015)... WOODBRIDGE, ON , March 26, 2015 /PRNewswire/ - Pivotal ... specialty pharmaceutical company with a focus on Omega-3 therapies ... March 25, 2015 it issued 763,752 common shares of ... payment of interest for the period of December 5 ... on its outstanding Convertible Notes that is due on ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... 16, 2011 DecisionView Inc., a leading provider ... for life sciences companies, today announced that a ... Roche have agreed to participate in the creation ... based on real-world clinical performance data. Each of ...
... N.J., June 16, 2011 Ferring Pharmaceuticals Inc. proudly ... Houston in an effort to help increase awareness about ... of healthy aging. The NSG is ... and is organized by the National Senior Games Association, ...
Cached Medicine Technology:DecisionView to Create Clinical Trial Enrollment Benchmarks 2DecisionView to Create Clinical Trial Enrollment Benchmarks 3Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 2Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 3Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 4
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part ... the latest and coolest applications on the market for ... NewsWatch and technology expert, conducted the app review and ... runner game with knights, nature, and peasants. , ... according to Eurogamer. The popularity of these games grew ...
(Date:3/28/2015)... New York, New York (PRWEB) March 28, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. ... multidistrict litigation underway in U.S. District Court, Southern ... Jeffrey S. Grand, is serving on the Plaintiffs’ ... March 24th, the Court has granted certain defendants ...
(Date:3/28/2015)... Orlando, FL (PRWEB) March 28, 2015 ... pre-existing conditions coverage is made available to all visitors ... States, effective immediately. All members are encouraged to purchase ... finalized to avoid lack of proper coverage for pre-existing ... suffer from one or two medical conditions with serious ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... correlate with a history of shoulder and elbow injuries, according ... for Sports Medicine’s ( AOSSM ) Specialty Day. , “Our ... associated with a 20% increase in likelihood of a history ... is associated with a 12% increase likelihood of a history ...
(Date:3/28/2015)... Delaying rotator cuff surgery on patients with ... presented today at the American Orthopaedic Society for Sports ... compared results for 170 patients who received rotator cuff ... capsule release procedure to relieve stiffness at the time ... from St. George Hospital in Sydney, Australia. “Both groups ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2
... a combined treatment of hormonal therapy and the drug, Herceptin ... breast cancer by over half, according to a recent report. ... the treatment to be made available for even more women ... addition of Herceptin to hormonal therapy kept a control over ...
... The 'baby-boom' of the 1960s and 1970s is largely ... services for people with an intellectual disability // ... reveals that the demand for intellectual disability services is ... of the best levels of service provided and huge ...
... was made at a major conference on brain tumours in ... , ,According to the Irish Cancer Society, in spite of ... rate of success and any damge to the delicate tissue ... there were 316 new cases of primary brain tumour diagnosed ...
... novel method of protection against bird flu has been studied and ... Rochester. // This involves a way of getting around the problem ... months to develop a vaccine. Also, two doses of vaccine would ... study is a" prime and boost" method of vaccination. An initial ...
... would be safer to carry out a stomach-stapling surgery by ... // ,Around 1 million bariatric surgeries ... recommended for weight loss and it involves stapling of the ... ,“Doing the surgery without incisions will make it ...
... mysterious viral outbreak has forced a Canadian University to shut ... This is thought to be a Norwalk-type virus that has ... New Brunswick and in the surrounding university town of Sackville. ... officials to investigate the outbreak. ,"They spent three hours on ...
Cached Medicine News:Health News:Awake Surgery to treat Brain tumours 2Health News:NOTE surgery – to combat obesit 2Health News:Mystery outbreak causes Canadian University to shut down 2
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: